Bortezomib

Bortezomib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Myeloid Leukemia、TP53、Relapsed or Refractory Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Bortezomib 研究

• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

  II 期招募中意大利NCT04915248

• Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

  II 期招募中德国NCT03993262

• Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

  II 期招募中美国NCT04991103

• Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

  不适用招募中瑞典NCT06245629

• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  III 期招募中美国Argentina澳大利亚奥地利NCT05623020

• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  III 期招募中美国NCT06022939

• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

  IV 期招募中中国NCT03844360

• Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

  II 期招募中西班牙NCT07045909

• A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

  不适用招募中中国NCT06497738

• Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

  早期 I 期招募中美国NCT06142396

• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  II 期招募中美国NCT03136146

• A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

  III 期招募中中国NCT06464991

• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

  I 期招募中中国NCT06900647

• An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

  II 期招募中GreeceNCT06636552

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  III 期招募中美国Argentina澳大利亚比利时NCT06152575

• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

  IV 期招募中中国NCT06409702

• Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

  I 期 / II 期招募中美国NCT05289167

• International Study for Treatment of High Risk Childhood Relapsed ALL 2010

  II 期招募中澳大利亚奥地利比利时CzechiaNCT03590171

• Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

  不适用招募中中国NCT06682156

• A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

  III 期招募中中国NCT07579234

• TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  I 期 / II 期招募中美国加拿大NCT05848687

• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

  III 期招募中中国NCT07623798

• The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

  II 期招募中South KoreaNCT05599880

• Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma

  II 期招募中IndiaNCT07891923

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。